Display Settings:

Format

Send to:

Choose Destination
J Clin Endocrinol Metab. 2012 Oct;97(10):3476-86. doi: 10.1210/jc.2012-1384. Epub 2012 Jul 12.

A new combination of testosterone and nestorone transdermal gels for male hormonal contraception.

Author information

  • 1Department of Medicine, Harbor-University of California, Los Angeles, Medical Center and Los Angeles Biomedical Research Institute, 1000 West Carson Street, Torrance, California 90509, USA.

Abstract

CONTEXT:

Combinations of testosterone (T) and nestorone (NES; a nonandrogenic progestin) transdermal gels may suppress spermatogenesis and prove appealing to men for contraception.

OBJECTIVE:

The objective of the study was to determine the effectiveness of T gel alone or combined with NES gel in suppressing spermatogenesis.

DESIGN AND SETTING:

This was a randomized, double-blind, comparator clinical trial conducted at two academic medical centers.

PARTICIPANTS:

Ninety-nine healthy male volunteers participated in the study.

INTERVENTIONS:

Volunteers were randomized to one of three treatment groups applying daily transdermal gels (group 1: T gel 10 g+NES 0 mg/placebo gel; group 2: T gel 10 g+NES gel 8 mg; group 3: T gel 10 g+NES gel 12 mg).

MAIN OUTCOME VARIABLE:

The main outcome variable of the study was the percentage of men whose sperm concentration was suppressed to 1 million/ml or less by 20-24 wk of treatment.

RESULTS:

Efficacy data analyses were performed on 56 subjects who adhered to the protocol and completed at least 20 wk of treatment. The percentage of men whose sperm concentration was 1 million/ml or less was significantly higher for T+NES 8 mg (89%, P<0.0001) and T+NES 12 mg (88%, P=0.0002) compared with T+NES 0 mg group (23%). The median serum total and free T concentrations in all groups were maintained within the adult male range throughout the treatment period. Adverse effects were minimal in all groups.

CONCLUSION:

A combination of daily NES+T gels suppressed sperm concentration to 1 million/ml or less in 88.5% of men, with minimal adverse effects, and may be further studied as a male transdermal hormonal contraceptive.

PMID:
22791756
[PubMed - indexed for MEDLINE]
PMCID:
PMC3462927
Free PMC Article

Images from this publication.See all images (5)Free text

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Write to the Help Desk